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Abstract
Bacterial sortases have been widely studied for their usefulness in protein
modification, however, the variable substrate specificity and activity between
homologs of these enzymes is not yet fully characterized. To attempt to further
understand sorting signal recognition, we have made advances towards a
substrate bound structure of Streptococcus pneumoniae sortase A (SrtApneu).
This enzyme displays a wide tolerance for alternate amino acids within the
canonical LPXTG sorting motif. Our strategy involves a non-cleavable peptide
analog that can be docked into the active site, allowing for elucidation of a
structure displaying the key contacts that allow the enzyme to recognize alternate
sorting signals. To this end, ketomethylene-linked isosteres were designed and
synthesized, one of which was incorporated into a peptide via solid phase
synthesis to produce a non-cleavable sorting signal for SrtApneu. Preliminary
analysis of the substrate analog LPAG(keto)G for inhibition of SrtApneu activity in
a model transpeptidation reaction suggested that this peptide was an effective
inhibitor. Work towards understanding the activity of SrtApneu in relation to its
oligomeric state was also undertaken, revealing a strong relationship between
the extent of oligomerization and relative activity of SrtApneu, where extensive
oligomerization resulted in minimally active samples. Purification of SrtApneu
samples was optimized to produce pure monomeric samples of the enzyme,
which showed improved transpeptidation activity. This work has helped lay the
foundation for future efforts in producing a substrate-bound structure of SrtApneu.
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1. Introduction
1.1 Protein Engineering and Sortase A
Protein engineering chemistry is a rapidly growing field of research,
proven to be broadly applicable to problems in chemistry, molecular biology, and
medicine. In many cases, protein engineering seeks to endow proteins with
expanded functionality through a variety of permanent modification methods.1-5
Among the numerous methods available for protein modification,
chemoenzymatic systems have seen increasing use, aiding in the production of
fluorescent-labeled proteins,6 antibody-drug conjugates,7 and bioconjugated
nanoparticles,8 within a growing catalog of useful products. This method typically
provides site-specific and rapid attachment of a desired modification, achieved
through recognition and alteration of amino acids or sets of amino acids within a
protein of interest.2, 9 Frequently, genetic modification is used to produce a
recognition site for an enzyme with the ability to catalyze addition of a desired
modification. The range of modifications is vast, however; most enzymes for
protein modification function in exactly the same manner: a specific sequence of
amino acids is recognized and a modification is made to or within the recognized
site (Figure 1).
In general, an individual enzyme catalyzes only a single reaction, meaning
for each type of modification, a separate chemoenzymatic system exists.
Formylglycine generating enzyme (FGE) recognizes a CXPXR amino acid
sequence and modifies the cysteine residue to formylglycine co-translationally,10,

11

which can be used to generate oximes through reaction with hydroxyamines,11,

12

a simple click reaction. Lipoic acid ligase attaches lipoic acid to lysine within its

recognition sequence. This enzyme has been particularly useful in protein
modification, as alteration of its substrates to include the azide and alkyne click
handles has allowed for site specific incorporation of these selective and rapidly
derivatized groups.13 This enzyme has also been employed in studies of proteinprotein interactions.14 Biotin ligase also modifies the lysine sidechain within its
recognition sequence, attaching a biotin molecule to the ε-amine.15 Biotin often
functions as a site specific tag for binding biomolecules to materials, examples of
which include nanoparticles16 and quantum dots,17 as this small molecule
selectively and tightly binds to proteins avidin and streptavidin.

Enzyme recognition sequence
Modification to be added

Chemoenzymatically modified protein
Protein modification enzyme

Figure 1. Generalized schematic of chemoenzymatic modification of proteins. A
protein with an endogenous or inserted peptide recognition sequence (shown in
black) is recognized by the protein modification enzyme. The modification is
attached covalently within the recognition sequence.
The sortase enzyme family has been well studied for use in protein
modification. Sortases are transpeptidases found in Gram-positive bacteria18, 19,
2

all of which maintain a nucleophilic cysteine within their active site that serves as
the primary residue for catalysis.18, 20, 21 Sortases can be divided into multiple
classes (A-F)21, 22, each exhibiting different structural and biochemical traits,
some of which are shown in Table 1. Of most relevance to this study is the class
A sortase (SrtA), which resides on the extracellular membrane of bacteria,
embedded via a transmembrane domain18 that can be removed to produce
soluble, recombinant SrtA for use in vitro. In vivo, SrtA typically performs a
“housekeeping” function by anchoring multiple protein types to the extracellular
wall.18, 19, 23-26 It has been determined that many proteins appended to the cell
wall by SrtA are key virulence factors,27 including collagen adhesion proteins,28
fibronectin binding proteins,29-31 and immunoglobulin binders32 that aide bacterial
cell colonization and inhibit the host immune response. This in vivo function of
SrtA makes it a viable drug target in Gram-positive bacteria, as several studies
have shown that Gram-positive bacterial strains without SrtA exhibit reduced
virulence.33-37 This makes it prudent to develop an in-depth understanding of
sortase enzymology, as it may benefit the development of novel therapeutics to
replace the rapidly failing catalog of current antibiotic drugs.38 While many
advances have been made towards understanding specific homologs of SrtA,
other less studied homologs may serve as excellent targets for further analysis
as tools and drug targets.9, 29, 31, 39

3

Table 1. Sorting signals, substrates, and species specificity of all known sortase
classes. [from Bradshaw et al.21]
Sortase Class
Motif
Example
Species
Substrates
A
LPXTG
Surface proteins40 All low GC content
Gram-positive
bacteria
B

NP(Q/K)TN

Haem acquisition
proteins41

Low GC content
Gram-positive
bacilli and cocci

C

(I/L)(P/A)XTG

Pillin subunits42, 43

Both low and high
GC content Grampositive bacteria

D

LPNTA

Endospore
envelope
proteins44, 45

Bacillus species

E

LAXTG

Pili46

High GC content
Gram-positive
bacteria

F

Unknown

Unknown

Actinobacteria

As each class of sortase performs a separate set of functions, each also
recognizes its own sorting motif; typically a five amino acid sequence that is
accepted into the enzyme active site for modification.21, 22 Specifically, SrtA
homologs typically recognize an LPXTG motif,18, 19, 23, 24 where X is any amino
acid. In proteins containing this motif, it is followed by a string of hydrophobic
residues and a highly polar tail, dominated by arginine and lysine residues. This
full segment (the sorting motif, hydrophobic, and hydrophilic residues) is referred
to as a cell wall sorting signal (CWSS), as it indicates which proteins should be
embedded in the cell membrane and targeted for binding, cleavage, and ligation
4

to the peptidoglycan of the extracellular wall.23, 47, 48 While sortases vary in terms
of their sorting motif preferences, they are all believed to catalyze
transpeptidation reactions similiar to that depicted in Figure 2 for sortase A from
Staphylococcus aureus (SrtAstaph). In the case of SrtAstaph, the enzyme cleaves
between the threonine and glycine residues in the sorting motif, forming an acylenzyme intermediate that is resolved by an N-terminal amine nucleophile (in S.
aureus, the lipid II pentaglycine moiety within the peptidoglycan).26 After
transferring the substrate, the enzyme releases the newly fused protein, now
appended to the cell wall.
NH2

NH2

NH2

L
P
X
T
L
P
X
T
G

O

SH

Sortase A

NH2

G

S

L
P
X
T
(G)

H2N-GGGGG

Sortase A

+

5

Lipid II

+

(peptidoglycan
precursor)

protein

Staphylococcus aureus

Figure 2. In vivo mechanism of transpeptidation by SrtAstaph.

5

Lipid II anchored protein

The innate ability of sortases to catalyze site-specific ligations has been
used extensively in protein engineering chemistry to produce a large catalog of
proteins and peptides conjugated to fluorophores,49 nanoparticles,8 lipid
nanodiscs,50 other proteins,51 and even live cells52, 53 (Figure 3). The protein or
peptide ligation partners can function as either the amine nucleophile or
substrate (sorting signal) in the transpeptidation reaction, which further enhances
the versatility of this approach.51, 54-56 This has been used to modify the C- and Ntermini of proteins, in addition to surface loops.51, 56 Several homologs of sortase
have been used in protein modification efforts. While most studies are carried out
with SrtAstaph, several modifications have been demonstrated with the SrtA
homolog from Streptococcus pyogenes9, 49, 57 (SrtApyogenes) and, more recently,
with the evolved mutants of SrtAstaph, which demonstrate higher reaction rates,58
altered substrate profiles,58-60 and Ca2+ independence.61, 62
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O
-LPXT

S

acyl enzyme
intermediate

sortase A

aminoglycine nucleophile

H2N-(G)n-

H2N-G-XX

Label

LPXTG substrate

-LPXTG-XX

SH

site-specific
ligation

-LPXT(G)n-

sortase A

LPXTG

proteins/synthetic peptides

H2N-(G)n

LPXTG

solid support/particles

H2N-(G)n

LPXTG

cells

H2N-(G)n

Figure 3. Protein modification using in vitro transpeptidation catalyzed by SrtA.
This strategy can be applied to a variety of ligation partners, shown in the bottom
half of the figure, facilitating the construction of diverse protein fusions.
1.2 Expanded Substrate Tolerance of Sortase Homologs
In addition to increases in the diversity of protein engineering applications
that employ sortases, there have also been a number of studies focused on
circumventing critical limitations of the method itself. With respect to SrtAstaph,
slow reaction rates, reversibility, strict substrate specificity,63 and limited
acceptance of structurally diverse amine nucleophiles63-65 reduce the usefulness
of the enzyme for certain applications. Slow reaction rates can often be
overcome by altering reaction conditions and reversibility can be diminished by
7

the use of specially designed substrates.66, 67 Our lab has previously developed
substrates containing the Ni2+ binding motif GGHG on the C-terminus, which,
upon cleavage, demonstrated a reduced capacity to function as a nucleophile in
the reverse reaction to reform the substrate.66 Depsipeptides have also been
used effectively modify the N-terminus of proteins, as processing substrates with
an ester linkeage produces C-terminal fragments with no available amine,
eliminating the possibility the reverse reaction to regenerate the starting
material.67 In contrast to the issue of reversibility, substrate specificity and limits
of accepted nucleophiles cannot be overcome by modifying the materials or
conditions used in the reaction, as they are founded in enzyme structure and the
mechanism of catalysis. In response, multiple groups have now generated
evolved SrtA mutants with improved catalytic activity, modified substrate
tolerance, and independence from certain reaction cofactors.48-52 While useful,
these strategies often rely on laborious directed evolution strategies in order to
identify useful mutations. As a complement to these approaches, our group has
been exploring the reactivity of naturally occurring sortase homologs as a way to
further expand the scope and versatility of sortase-mediated protein engineering.
With respect to substrate specificity, bioinformatics studies suggest that
the vast majority of SrtA homologs are specific for LPXTG motifs68. Using the
CW-PRED2 algorithm, sortase substrates have been predicted from more than
177 bacterial genomes.61 SrtAstaph was predicted to have between 15 and 21
substrates across 13 strains, all of which demonstrated a high preference for
8

leucine in position 1, proline in position 2, threonine in position 4, and glycine in
position 5. Position 6 was also analyzed and demonstrated no preference for this
position in sortase substrates. Position 3, the variable position in the sorting
motif, was frequently occupied by a charged residue; however, no strong
preference for specific amino acids was determined for this position.
Interestingly, substrate prediction demonstrated that in about 10% of substrates,
the 4th position was occupied by alanine. In vitro analysis of these preferences
with discrete peptide substrates shows there are some discrepancies between
the actual and predicted sorting sequences of some sortase homologs.
Specifically, it has been demonstrated that SrtAstaph has a preference for glycine
in the 6th position, outside of the canonical LPXTG sorting motif.69 Further,
studies by Kruger et al. have demonstrated that SrtAstaph accepts several amino
acids in the 4th position of the sorting motif, a trait not predicted by bioinformatics
algorithms.69 Building from these initial studies, our group has now shown that
SrtA homologs can exhibit substantial differences in tolerance for amino acids in
multiple positions of the sorting sequence. The most substantial deviations from
the canonical LPXTG sorting motif were found in the 4th and 5th positions of the
amino acid sorting sequence. An example for the 5th position tolerance is shown
in Table 2. These data revealed that many SrtA homologs accept several amino
acids in the 5th position of the sorting sequence. A particularly wide tolerance to
substrates with non-canonical amino acids in the 5th position can be seen in
Streptococcus pneumoniae SrtA (SrtApneu).
9

sortase A

Abz-LPATZG-K(Dnp)
Sortase A
homolog

Abz-LPAT-NHOH

H2N-OH
excess

ZG-K(Dnp)

+

Z = V

Y

S

W

L

Nle

G

A

N

F

Q

C

S. aureus

3

1

1

0

0

0

86

2

0

1

2

5

S. suis

2

2

67

0

0

2

71

74

58

3

3

73

S. oralis

2

1

54

0

0

1

74

46

3

2

6

48

S. pneumoniae

39

14

84

11

41

14

81

92

48

29

11

76

L. monocytogenes

4

43

41

6

1

2

86

15

22

30

1

42

E. faecalis

1

0

7

0

0

1

7

5

6

3

1

10

L. lactis

5

1

44

0

1

1

83

66

28

2

1

32

B. anthracis

1

2

8

0

0

1

42

22

17

1

0

17

L. plantarum

1

1

2

0

3

0

18

3

2

1

1
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Figure 4. Amino acid preferences of selected SrtA homologs for the 5th position
of the SrtA recognition sequence LPXTG [Nikghalb, Antos unpublished data].
In addition to the expanded substrate tolerance, the reaction completion
percentages determined by HPLC and MS analysis of these model sortasecatalyzed ligation reactions demonstrate that SrtApneu prefers the substrate
LPATA in vitro, instead of the canonical LPXTG substrate. This is in clear
contrast to SrtAstaph, which prefers only LPATG containing substrates. While
some conversions are sub-optimal for use in protein engineering applications, the
tolerance data shown in Figure 4 above is the result of unoptimized reactions,
and even low percent conversions may be improved by modifying the reaction
conditions. Importantly, this would provide a route for expanding the scope of the
sortase-mediated protein engineering, potentially increasing the range of
endogenous protein targets that are compatible with sortase without the need to
insertion of a recognition sequence in the primary structure, ultimately saving
10

time and resources.
Regarding the homolog SrtApneu, its particularly broad substrate tolerance
presents an interesting issue to be examined with respect to the mechanism of
substrate recognition. It is known that SrtAstaph undergoes structural
rearrangement upon correct substrate binding, which facilitates catalysis of
transpeptidation.70, 71 The wide substrate tolerance described above for SrtApneu
suggests that it may harbor a unique mode of substrate recognition. A thorough
understanding this substrate recognition at the molecular level would benefit not
only the continued development of SrtApneu for use in protein engineering, but
would also contribute to our fundamental understanding of sortase enzymology.
Unfortunately, no structure of SrtApneu has been published to date, which
precludes a more in depth analysis of its substrate recognition and catalytic
mechanism.

1.3 Substrate Binding and Structure of SrtA Homologs
Published solution NMR structures have been determined for SrtAstaph71
and sortase A from Bacillus anthracis (SrtAanth)72 with a bound substrate analog,
referred to as LPAT*, which utilizes a disulfide bond forming linker on the Cterminus that irreversibly binds to the enzyme active site.71 These structures
have been instrumental in developing an understanding of the reverse
protonation mechanism of catalysis73 and the enzyme-substrate interactions of
the first four amino acids within the sorting sequence.
11

A

B

β7/β8 loop

β7/β8 loop

β6/β7 loop

β6/β7 loop

S. aureus SrtA
(PDB ID: 2KID)

S. pneumoniae SrtA (from Phyre 2)

C
ARG-197
VAL-166

CYS-184

HIS-120

ILE-182
LEU-169

TRP-194

ALA-118

Figure 5. (A) Solution NMR structure of SrtAstaph. Arginine (blue), cysteine
(yellow), and histidine (green) stick structures represent the key catalytic
residues. (B) Predicted structure of SrtApneu from the Phyre 2 structural prediction
server74. (C) Active site architecture of the solution NMR structure of SrtAstaph
with the bound substrate analog LPAT* (PDB ID: 2KID). Side chains of residues
surrounding the active are shown as stick structures, highlighting the number of
hydrophobic interactions stabilizing the substrate-bound state.
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In terms of overall structure, sortases include an 8-stranded beta barrel
fold considered to be unique to this family of enzymes.20 This β barrel is
surrounded by combinations of α and 310 helices and loops that vary in size and
conformation between classes and homologs.21, 23, 72, 75-77 In general, SrtA
homologs contain three catalytic residues: cysteine, arginine, and histidine, within
the active site.78, 79 In SrtAstaph, the active site floor, or binding groove, is formed
from strands β4 and β7 (Figures 5 and 6). The walls of this binding pocket are
composed of loops joining other β strands and α helices in the structure. Within
the active site, bound substrates are found in an “L” shape, facilitated by the
proline residue, which angles the scissile bond towards the active site cysteine.
The leucine sidechain makes hydrophobic contacts with residues in the β6/β7
loops and proline is buried in a hydrophobic groove formed by residues of the β4
and β7 strands. The alanine residue displays a hydrophobic interaction with the
H1 helix, however, it is important to note that space exists for projection of larger
sidechains away from the enzyme, partially explaining the low specificity for
amino acids in this position. The threonine in the 4th position of the amino acid
sorting motif functions forces the sidechain of a tryptophan residue up and away
from the active site, moving the catalytic cysteine residue towards the scissile
peptide bond.71 This is considered to be one of the most important interactions in
substrate recognition, as substrates with glycine at this position are completely
inactive63.
Binding of the sorting motif in the active site induces further
13

conformational changes in some homologs of SrtA. In SrtAstaph, loop β6/β7
undergoes a large disordered to ordered transition which is key to substrate
binding, as the recognition of the sorting sequence leucine residue relies on
multiple interactions in this strand.71, 80-82 The nucleophilic attack of the scissile
peptide bond by the active site cysteine shifts the β7/β8 loop to reveal the
backside of the active site to incoming nucleophiles.71 This also facilitates
recognition of the threonine residue, as mentioned above. The size of the β7/β8
loop is predicted to be important for recognition of the 5th position in the amino
acid sorting sequence (Nikghalb and Antos, unpublished data). SrtAstaph displays
a particularly large loop extending from the β7/β8 strands (Figure 5), which may
account for the high selectivity for glycine in the 5th position of the sorting
sequence.
Apart from SrtAstaph, NMR data for SrtAanth bound to the LPAT* substrate
analog72 shows a number of similar features, including the cys-his-arg catalytic
triad and the structure of the substrate binding groove. The binding pocket in this
enzyme appears to be mostly preformed, however, in contrast to that of
SrtAstaph.72 Other notable differences between these structures exist, particularly
the direction of the threonine residue, which points down towards the guanidino
group of arginine. This supports the presence of an oxyanion hole to stabilize the
tetrahedral transition state in the catalytic cycle, as initially hypothesized from the
structure of SrtBanth.83 Additionally, the β7/β8 loop of this homolog demonstrates
a similar structural transition upon substrate binding to that of SrtAstaph β6/β7
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loop, whereas the β6/β7 loop of is ordered in both the apo and substrate-bound
forms of the enzyme. An interesting N-terminal appendage, similar to that seen in
the SrtC subclass,84 is thought to protect the active site from hydrolysis of the
substrate, facilitating reactivity with the intended N-containing nucleophile72.
While a structure of SrtApneu bound to a substrate analog has not been
reported, structure prediction tools reveal features that may play a role in the
expanded substrate tolerance of this enzyme. One-to-one threading by the
Phyre274 structural prediction server has allowed for prediction of the structure of
SrtApneu (Figure 5). SrtApneu is predicted to have a smaller β7/β8 loop than that of
SrtAstaph, which could account for its increased substrate promiscuity, as this
region should be involved in recognition of amino acids in the 4th and 5th position
of the sorting sequence.
Another variable aspect of SrtA structure and substrate recognition can be
seen in metal ion sensitivity. Many sortases20, 85-87 are Ca2+ dependent, where the
bound ion improves the catalytic activity of the enzyme. SrtAstaph binds calcium
with a set of acidic residues in the β6/β7 loop, stabilizing the substrate bound
conformation70, 71, 80. The presence of Ca2+ ion in reactions with this homolog
significantly increases the reaction rate20. Again, in contrast to SrtAstaph, sortases
have also been discovered which are independent of Ca2+ ion88, 89. A recently
determined example of this is Streptococcus suis SrtA (SrtAsuis), where Ca2+ ion
has no effect on reaction rate or total conversion. Our lab has previously
determined that Ca2+ ion has little to no effect on the reaction rates of SrtApneu,
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which indicates it may recognize and bind substrates in a mechanism
fundamentally different than SrtAstaph.
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Figure 6. (A) Surface structure representation of SrtAstaph with the bound
substrate analog LPAT* (green). (B) Mechanism of transpeptidation within the
active site of SrtA. The red box denotes the acyl-enzyme intermediate that
closely resembles the structural state of the structure at left.
Unfortunately, these structures lack a complete description of substrate
binding and recognition, as they do not illustrate interactions between the fifth
position of the sorting sequence and the enzyme. The substrate analog used to
collect the data from the studies by Suree et al.71 and Chan et al.72 closely
mimics the acyl-enzyme intermediate, designated in Figure 6 by the red box,
which involves only the first four amino acids (LPAT) in the sorting motif. That
said, additional work by Suree and coworkers has revealed some regions of
SrtAstaph implicated in recognition of the nucleophile and fifth amino acid
positions71 (Figure 7). 15N-HSQC monitored titration of triglycine resulted in three
regions displaying perturbed backbone resonances, presumably from the binding
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of triglycine to these regions. These amino acids primarily lie around the sites
where the 5th position amino acid should contact the binding pocket. Interestingly,
sequence alignment of various SrtA homologs displays a marked difference in
primary structure in these regions (Figure 7). This correlates with data from our
lab (Figure 4) demonstrating the greatest differences from canonical LPXTG
sorting motif recognition occur in the fifth amino acid, and highlights the need for
a more rigorous assessment of contacts between the 5th position amino acid and
SrtA during substrate recognition.
Region 1
Region 3
Region 2

Region 2

Region 1

Region 3

Figure 7. (A) Sequence alignment of selected SrtA homologs90, 91. The regions of
greatest difference (boxed) correspond to the regions highlighted in the structure
(B), indicating the least sequence homology lies on the structural features
predicted to interact with the 5th position of the sorting sequence. (B) Surface
representation of SrtAstaph bound to substrate analog LPAT* (PDB ID: 2KID).
Residues highlighted in magenta were determined to interact with the incoming
nucleophile by analysis of peak perturbation during a 15N-HSQC monitored
titration of SrtAstaph with G3. These residues primarily lie around the region of the
binding pocket predicted to interact with the C-terminus of the sorting signal.71
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1.4 Enzyme Activity as a Function of Oligomeric State and Active Site
Modifications
Previous studies have demonstrated the presence of both dimeric and
monomeric forms of SrtA both in vivo and in vitro.87, 92-94 In vitro, SrtAstaph samples
were subjected to several modes of analysis to confirm the presence of
oligomers (Figure 8) and assess the strength of the dimer association.
Specifically, analytical sedimentation equilibrium ultracentrifugation calculated an
average Kd for the monomer-dimer equilibrium to be 54.6 ± 6.9 µM, considered a
moderate interaction between the subunits of the complex.92 In vitro, SrtAstaph
catalytic activity has been evaluated for both the monomeric and dimeric forms of
the enzyme, where ligation reactions performed with monomeric preparations did
not function as well as those with high concentrations of the homodimer.92 The
dimer was predicted to be as much as 8 times as active as the monomer based
on steady state analysis of reactions at various concentrations (Figure 9).

Figure 8. In each panel, lane 1 is Coomassie staining and Lane 2 is Western
Blotting with anti-His6x antibody. (A) SDS-PAGE analysis of truncated SrtAstaph.
(B) SDS-PAGE analysis of wild-type SrtAstaph. (C) Native PAGE analysis of
truncated SrtAstaph. (Adapted with permission from Lu et al.92 Copyright 2007
American Chemical Society)
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Figure 9. Steady state reaction velocity analysis with varying [LPETG] for (A)
monomer and (B) dimeric SrtAstaph. (Adapted with permission from Lu et al.92
Copyright 2007 American Chemical Society)
In vivo, Zhu et al. demonstrated that higher levels of monomeric SrtA
increase the amount of sortase-catalyzed surface attached protein by inserting a
non-dimerizing mutant of SrtA into a knockout strain of S. aureus.93, 94 This
indicated greater catalytic activity for the monomeric form, in clear contrast to the
in vitro studies. Further, the increased presence of surface attached proteins
rendered bacteria with fully monomeric sortase more invasive than the wild-type
strain. The dimerization observed in this homolog is anticipated to be biologically
relevant as a mechanism for deactivating the enzyme when rapid attachment of
proteins to the cell wall is not necessary.92, 94 Dimerization has been observed as
a mechanism of regulation in other enzymes.95 Analysis of this monomer-dimer
interplay has not been performed in other homologs of SrtA, however, based on
the data above it is an essential piece of regulation which is not yet understood.
Regarding the modes of oligomerization available to SrtAstaph, it is not
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certain how this enzyme associates in vivo or in vitro, as no structure has been
published to demonstrate this phenomenon. The crystal structure of SrtAstaph96
helped guide Zhu et al. in developing a set of mutants with diminished
dimerization capacity. SrtAstaph with any one of the mutations Y143A, K137A, or
N137A demonstrated greater than 93% lower dimerization than the original
truncated SrtAstaph. From these data, the authors hypothesized the Y143 and
K137 mutations may disrupt a cation-π interaction which initiates dimerization.
Cation-π interactions are seen in other proteins to facilitate dimerization and are
often stabilized by additional charge interactions,97-99 which is believed to be why
mutation of N137 also diminishes the presence of the sortase dimer. These
contacts would facilitate structural rearrangement to create further hydrophobic
and hydrogen bonding, generating stable homodimers.93
Further information relevant to the work described here comes from a
structure of SrtApneu (PDB ID: 4O8L) deposited in the Protein Data Bank but not
yet published in a written article. This x-ray crystallography structure shows a
domain swapped dimer, where a large portion of the anticipated active site
associates with the complimentary enzyme (Figure 10). More specifically,
strands β7 and β8 and loops β6/β7 and β7/β8 are rotated out of the enzyme core
structure to form contacts with the opposite monomer in the domain swapped
dimer. Enzymes in this state would most likely be inactivated, as the catalytic
cysteine residue lies on β7 loop, and is therefore buried in the domain swapped
form. While it is not known if this structure is an artifact of enzyme preparation or
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an authentic representation of the enzyme in vitro, it does demonstrate the ability
of SrtApneu to form stable, potentially inactivated, dimer constructs.

A

B
β7/β8 loop

C

β6/β7 loop

Figure 10. (A) The domain swapped dimer of SrtApneu (PDB ID: 4O8L) (B) A
domain swapped monomer from the structure of SrtApneu in (A). (C) Predicted
structure of SrtApneu from the Phyre274 structural prediction server. In both
structures, the green colored areas pertain to the domain swapped portion of the
structure shown in (A).
An additional factor that may contribute to sortase activity comes from the
crystal structure of SrtApyogenes, where a stable sulfenic acid modification was
discovered in the active site of a crystal structure.75 The sulfenic acid modification
discovered was anticipated to be of a non-active form of the enzyme, as the
active site cysteine would no longer be available to function as the primary
nucleophile in catalysis. Interestingly, the modified cysteine stimulated
conformational change in the enzyme similar to what is anticipated to occur with
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a bound substrate, suggesting that structural rearrangement is an essential
aspect to the mechanism of transpeptidation in SrtApyogenes.75 The authors
predicted that this could be biologically relevant as a potential method of
inactivation by host immune systems releasing reactive oxygen species.
McCafferty et al. determined that the reverse protonation mechanism of SrtAstaph
confers protection from oxidation onto the active site cysteine, as the high pKa of
this residue side chain resists oxidation.100 More recently, use of reactive Cu
chelating peptides has demonstrated the potential for the active site cysteine of
SrtAstaph to be oxidized to sulfenic acid, which the researchers in this study
suggested would function as a form of irreversible activation101.
1.5 Project Goals and Overview
Given the importance of sortases as tools for protein engineering and as
targets for therapeutic development, it is critical to establish a detailed
understanding of substrate recognition among homologs with diverse substrate
tolerances. To this end, the long-term goal of this project is to determine the
structure of the promiscuous enzyme SrtApneu covalently docked with substrate
analog. As described in this thesis, our approach involves the construction of
ketomethylene-based sorting signal analogs, which we anticipate to be noncleavable by the sortase enzyme (Figure 11). Importantly, the use of
ketomethylene dipeptide isosteres will mimic amino acids in the 4th and 5th
position of the sortase substrate motif, allowing for elucidation of key interactions
between the enzyme and these residues. In addition, we believe this can provide
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a more complete picture of substrate recognition in SrtA, and more specifically,
the homolog from S. pneumoniae, as there is currently no published data
regarding this enzyme’s structure. Here we describe progress toward
synthesizing the requisite ketomethylene building blocks, as well as preliminary
evidence indicating that these substrate analogs are able to interact with the
enzyme active site. We also describe an unanticipated oligomerization of
recombinant SrtApneu, and the development of methods for refolding, purifying,
reproducibly generating preparations of SrtApneu with consistent activity. These
studies provide an important foundation both for utilizing SrtApneu as a tool for
protein engineering, and for further structural characterization of this enzyme.
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Figure 11. Anticipated mechanism of trapping for the proposed ketomethylene
substrate analogs.
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2. Preparation and Characterization of Recombinant
Streptococcus pneumoniae sortase A (SrtApneu)
2.1 Expression, Refolding and Purification of SrtApneu
Initial work on this project was aimed at producing a stock of SrtApneu to be
used for structural characterization. To this end, an expression vector for SrtApneu
was obtained via commercial gene synthesis from DNA 2.0, which encoded a
truncated version of SrtApneu fused to an N-terminal His6 tag. In this construct, the
first 80 amino acids, corresponding to the hydrophobic transmembrane region,
were removed to increase solubility in aqueous buffers. Initially, SrtApneu was
expressed from E. coli BL21(DE3) using standard molecular biology techniques.
After cell lysis, the enzyme was isolated from the soluble fraction using
immobilized metal affinity chromatography (IMAC). Prior work in the laboratory
had succeeded in producing an active preparation of this enzyme, hereafter
referred to as batch 1. An additional enzyme stock was generated for this work
(batch 2) using a batch purification protocol for initial binding of enzyme to nickel
nitriloacetic acid (Ni- NTA) resin. The eluted material from the first round of
purification was re-purified through standard gravity-flow IMAC protocols to
improve the purity of these samples. The sodium dodecyl sulfate polyacrylamide
gel electrophoresis (SDS-PAGE) analysis of batch 2 (Figure 12) showed an
intense band near 26 kDa, in reasonable agreement with the calculated
molecular weight of 20.1 kDa for SrtApneu This gel also demonstrated the good
purity and high concentration of the collected samples. We also observed what
24

appeared to be SrtApneu dimer at ~50 kDa that persisted in the sample despite the
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Figure 12. SDS-PAGE gel showing samples from the expression and purification
of batch 2 SrtApneu prepared from IMAC purification using Ni-NTA resin.
Model sortase-mediated ligation (SML) reactions using a known peptide
substrate (Abz-LPATA-GK(Dnp)) and the strong nucleophile H2NOH were used
to assess the in vitro reactivity of batch 2 (Figure 13). After a 24 hour incubation
at room temperature, the reactions were analyzed by reverse phase high
performance liquid chromatography (RP-HPLC). Surprisingly, the batch 2
enzyme stocks produced only minimal product formation (4.8% reaction
conversion) when compared to the batch 1 positive control (95% conversion).

25

Abz-LPATAG-K(Dnp)

SrtApneu
H2N-OH
excess

Abz-LPAT-NHOH + AG-K(Dnp)

Absorbance (330 nm)

AG-K(Dnp)

RP-HPLC
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Batch 1 SrtApneu
Batch 2 SrtApneu
0

5
Elution time (min)

10

Figure 13. RP-HPLC analysis of model SML reactions demonstrating the
difference in activity between batches 1 and 2 of SrtApneu. Reactions were
analyzed after 24 hrs of incubation at room temperature. 40 µM Abz-LPATAGK(Dnp) was used in this reaction.
As a result of the low observed reactivity for batch 2, a new batch of
SrtApneu (batch 3) was expressed and purified by standard IMAC protocols from
newly transformed E. coli to eliminate the possibility of issues with the previous
cell line (Figure 14). As expected, an intense band was seen around 26 kDa,
matching closely to the expected molecular mass of SrtApneu from SDS-PAGE
analysis. We further analyzed these samples through mass spectrometry.
Reconstruction of the enzyme molecular mass from the observed charge ladder
(Figure 15) returned an uncharged mass of 20145 Da (expected MW = 20145
Da). Model SML reactions prepared from the batch 3 SrtApneu also demonstrated
low reactivity (Figure 16), where only 21% conversion of the peptide substrate
was observed.
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Figure 14. SDS-PAGE gel representative of SrtApneu batch 3 samples prepared
from IMAC purification using Ni-NTA resin.
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Figure 15. (A) ESI-MS spectrum of batch 3 SrtApneu (B) Deconvoluted mass
spectrum of SrtApneu batch 3. The primary mass shown here, 20145 Da, is
identical to that predicted for this SrtApneu truncation.
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Abz-LPATAG-K(Dnp)

SrtApneu
H2N-OH
excess

Abz-LPAT-NHOH + AG-K(Dnp)

~95% conversion
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Figure 16. RP-HPLC analysis of model SML reactions demonstrating the
difference in activity between batches 1 and 3 of SrtApneu. Reactions were
analyzed after 24 hrs of incubation at room temperature.
To further investigate the observed discrepancy in enzyme reactivity, we
analyzed our catalog of SrtApneu samples by native PAGE (Figure 17). In
contrast to reducing SDS-PAGE, which suggested that all enzyme stocks were
monomeric and identical, native PAGE revealed some striking differences. In
particular, native PAGE revealed a number of higher molecular weight bands in
all samples of SrtApneu. Based on the absence of these prominent bands under
denaturing conditions, we hypothesized that they represented oligomers of the
enzyme, a phenomenon known to occur in other sortase homologs.87, 92, 94
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Interestingly, batch 1 SrtApneu, which exhibited good in vitro reactivity and was
used as a positive control in model SML reactions, showed a stark difference in
the oligomer/monomer ratio when compared to newly prepared samples (batch 2
and batch 3). Specifically, batch 1 in lane 1 contained a lower concentration of
oligomerized sortase bands, particularly in the area that we propose corresponds
to trimeric and tetrameric SrtApneu, in addition to a higher concentration of
monomer than batch 2 and 3 samples in lanes 2 and 3, respectively. While both
batch 2 and batch 3 samples demonstrated oligomerization in this analysis, we
elected to continue our analysis with the batch 3 SrtApneu samples, as these had
been developed using identical IMAC purification procedures used in the lab.
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Figure 17. Native PAGE gel demonstrating the presence of potential oligomeric
states in stocks of SrtApneu. Samples were loaded in equimolar amounts. The
predicted subunit count is given at right for each boxed region. Of particular
interest here are lanes 1 and 3, which demonstrate variation in the band patterns
between batch 1 and batch 3 SrtApneu. Specifically, batch 1 shows a smaller
amount of higher molecular mass bands than batch 3, and a greater
concentration of protein anticipated to be the SrtApneu monomer. Lane 2 came
from the batch 2 SrtApneu expression and also displays the oligomerized band
pattern, which differs from that of batch 1.
The presence of SrtApneu in solution was further confirmed by size
exclusion fast protein liquid chromatography (SE-FPLC), which was able to
resolve samples of SrtApneu into its assembled components (Figure 18).
Resolution of different molecular weight species was clearly seen in FPLC
traces, and native PAGE analysis of fractions from SE-FPLC separation showed
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the same band pattern as unprocessed samples of the enzyme (Figure 19).
Based on these data, it was concluded that SrtApneu exists as about 93%
oligomer in batch 3, which we reasoned was interfering with the enzymatic
activity of the new preparation. In addition, given that the most active prep of
SrtApneu (batch 1) appeared to have the highest monomer content (Figures 16
and 17), we hypothesized that the monomer was the active form of the enzyme.

Oligomers

Absorbance (280 nm)

SE-FPLC

Monomer

8

12

10

14

Elution volume (mL)

Figure 18. SE-FPLC trace demonstrating the presence of multiple oligomeric
species in a pure sample of batch 3 SrtApneu. This sample was separated at a
0.75 mL/min flowrate.
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Figure 19. Native PAGE of the SE-FPLC fractions 8-11 from the separation in
Figure 18. Similar band patterns can be seen in the fractions as in a sample of
the injected batch 3 SrtApneu in lane 1.
To begin to explore this phenomenon and understand how to generate
fully active, monomeric SrtApneu preparations, samples were subjected to
conditions that potentiated disassembly of the enzyme oligomers. First attempts
at this involved incubation of serial diluted samples of the batch 3 stock at room
temperature to evaluate the possibility of high stock concentrations forcing the
monomer-oligomer equilibrium towards the oligomerized state. Unfortunately, the
presence of high molecular weight bands seen in native PAGE analysis of these
diluted samples was unchanged (Figure 20). Notably, this observation did not
align with previous accounts of sortase dimerization, as the dissociation constant
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determined for SrtAstaph dimer/monomer equilibrium (55 µM) suggested that the
low affinity interactions between monomers would favor dissociation at low
concentrations92. This indicated that SrtApneu oligomerization could be
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Figure 20. Native PAGE gel of room temperature incubated serial dilutions of
batch 3 SrtApneu.
Fortunately, further attempts at disassembling SrtApneu were more
successful. We next reasoned that oligomerization could be dependent on
temperature. To evaluate this, samples of batch 3 SrtApneu were incubated at 37
o

C and room temperature for 24 hours at 50 µM, 100 µM, and 300 µM

concentrations. The relative disassembly of the putative oligomers was analyzed
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via native PAGE. It was immediately apparent from native PAGE that incubation
at 37 oC for 24 hrs degraded the oligomers into monomeric enzyme, generating a
band pattern that was similar to the active batch 1 preparation (Figure 21). In
contrast, room temperature incubation yielded material that was identical to the
original batch 3 stock. Lower incubation concentrations also appeared to slightly
improve the monomer content, although this did not appear to be as substantial.
SE-FPLC analysis of undiluted samples of batch 3 SrtApneu heated for more than
24 hours also demonstrated an increase in peak area where the monomer was
expected, mirroring the results of native PAGE experiments for shorter incubation
times (Figure 22). Use of “heat-disassembled” batch 3 samples in a model SML
reaction resulted in greater product formation. In particular, enzyme samples
incubated at 37 °C for 1 week (Figure 23) produced conversion percentages of
95% after 48 hours, very near the batch 1 positive control reactions, which
exhibited 97% conversion in the same period of time (Figure 24). Reactions
using batch 3 SrtApneu produced only 35% conversion in this reaction set. This
indicated that the oligomerized states of the enzyme most likely exhibit some
control over the rate and effectiveness of SML. While incubation of batch 3
samples for extended periods of time (>24 hrs) resulted in somewhat greater
dissociation of high molecular weight bands (Figure 23), aggregation was also
observed in SE-FPLC traces of samples incubated for these extended periods of
time (Figure 22).

34

fied
)
odi

d)

U nm

difie
B at

ch1

sto

ck (

mo
(Un
ch
3

µM
100

B at

(RT

)

° C)
( 37
µM
100

50

µM

(RT

)

° C)
( 37
µM
50

Figure 21. Native PAGE gel demonstrating the effect of heating samples of
SrtApneu. Lanes 1 and 3 contain diluted samples of batch 3 enzyme heated for 24
hrs at 37 °C. The band patterns of the heated samples more closely resemble
that of the batch 1 samples in lane 6 than the batch 3 stock in lane 5.
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Figure 22. SE-FPLC traces showing the oligomer distribution in samples of
SrtApneu heated for (A) 3 days and (B) 7 days at 37 °C. A peak centered around
7.5 mL developed after longer periods of heating, anticipated to be aggregation
of the enzyme.
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Figure 23. Native PAGE gel demonstrating the effects of 7 days of incubation at
37 °C on diluted samples of batch 3 SrtApneu with and without 10 mM
dithiothreitol (DTT). As in Figure 21, the band pattern of the heat-treated batch 3
samples looks more similar to the batch 1 SrtApneu than untreated batch 3
SrtApneu.
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RP-HPLC
AG-K(Dnp)
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(Lane 6) Batch 1
Abz-LPATAG-K(Dnp)

Absorbance (330 nm)
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(Lane 3) 100 µM heated batch 3
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0
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Figure 24. RP-HPLC analysis of reactions assembled with preparations of
SrtApneu from the gel in Figure 23. Reactions were incubated at room
temperature for 48 hrs. The enzyme preparation used in the reaction is denoted
by the lane number at the right of the trace. Heated samples of batch 3 SrtApneu
produced similar conversion to the batch 1 stock reactions, which matches the
gel showing similar band patterns between the three samples.
Having succeeded in recovering some enzyme activity by heat treatment,
we next evaluated the behavior of heat-disassembled SrtApneu after prolonged
incubation at room temperature, 4 oC, or -80 oC, (Figure 25). None of these
treatments resulted in reversion of the native PAGE band pattern back to the
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initial assembled state, and the desired monomeric SrtApneu remained present.
Overall, this indicated the SrtApneu assembly process potentially involves an
equilibrium that favors the monomeric form of the enzyme. As mentioned
previously, however, dilution of the batch 3 stocks without heating did not appear
to diminish the presence of high molecular weight bands. Along with the
information collected from the heating experiments, this suggested the presence
of an activation barrier for converting between the monomeric and oligomeric
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Figure 25. Native PAGE gel showing batch 3 SrtApneu heat-disassembled for 24
hours at variable concentrations and incubated for 24 hours at room temperature,
4 °C, and -80 °C. All samples were loaded in equimolar amounts.

39

To apply the information gained from the heating experiments to
production of active SrtApneu samples, alternative expression temperatures were
tested to determine if production of the protein at lower temperatures would
minimize the oligomer concentrations. After expressions attempts at 16, 25, and
SE-FPLC
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37 oC, analysis by SE-FPLC determined there
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Based on the information gathered from the experiments described above,
we next sought to explore a redesigned protocol for purifying SrtApneu that would
maximize monomer content. After considering the data on heating to increase
monomer concentration, a denaturing purification step followed by refolding was
anticipated to provide a similar role as heating post-purification. Denaturation
during purification would presumably eliminate any intermolecular contacts or
domain swapping interactions that could hold together multiple units of the
enzyme. Therefore, the original purification protocol was modified to include an
initial denaturing purification with 8 M urea, where the E. coli were first lysed in a
denaturing buffer, the protein purified from clarified lysate in denaturing buffer via
IMAC, followed by the denatured sample being refolded with a non-denaturing
buffer. Figure 27 shows the analysis of SrtApneu refolding via a rapid dilution of
denatured SrtApneu into non-denaturing buffer (50 mM Tris pH 8.0, 150 mM NaCl)
followed by an additional IMAC step to concentrate the refolded, soluble enzyme.
Elution fractions from the rapid dilution refolding protocol were further purified by
SE-FPLC to separate the sample into monomeric and oligomeric forms (Figure
27). Analysis of SE-FPLC fractions by native PAGE analysis demonstrated that
SrtApneu fractions with high monomer content could be isolated, however, a high
relative concentration of enzyme was still trapped in the inactivated forms.
Unfortunately, when refolded, monomeric SrtApneu tested in a model SML reaction
continued to show diminished reactivity when compared to positive control
reactions employing batch 1 SrtApneu (Figure 28). This was surprising, as we had
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anticipated the pure monomer samples to perform as well as or better than batch
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Figure 27. (A) SDS-PAGE gel showing the purity of SrtApneu samples obtained
from Ni-NTA purification after denaturing and refolding steps. (B) Native PAGE
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Figure 28. RP-HPLC analysis of a model SML reaction prepared with SE-FPLC
purified monomeric SrtApneu from the denaturing purification protocol. This
reaction was incubated for 24 hrs at room temperature before analysis. Only
minimal processing of the substrate was observed, corresponding to 3.5%
conversion of the substrate.
To continue improvement of the SrtApneu preparations, we next explored
the use of reducing agents to promote oligomer disassembly and to ensure that
the active site cysteine residue remained in its fully reduced form. Preliminary
experiments with dithiothreitol (DTT) had demonstrated some efficacy for
restoring SrtApneu activity in vitro after a 22 hour incubation period at 37 oC
(Figure 29), where SrtApneu incubated with 10 mM DTT produced more product
(72% conversion) when compared to both unheated (21% conversion) and
heated (47% conversion) samples. To build on this initial result, DTT was
combined with prolonged heating at 37 oC. This resulted in even greater
dissociation of oligomerized SrtApneu, in addition to increased intensity of the top
band of the monomer doublet observed in native PAGE for SrtApneu (Figure 30).
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While these native PAGE results were promising, the enzyme treated with these
conditions failed to show any activity in vitro (Figure 29), despite the presence of
significant monomer content in the enzyme sample. This prompted us to replace
DTT with the non-sulfrous reducing agent tris(caboxyethyl)phosphine (TCEP).
To our satisfaction, we observed that addition of 10 mM TCEP to SE-FPLC
purified monomeric SrtApneu from the denaturing purification protocol greatly
improved the percent conversion observed in model SML reactions by RP-HPLC
analysis (Figure 31). Specifically, in the absence of TCEP, reactions reached
only 3.5% conversion, whereas in the presence of TCEP reaction conversion
increased to 60%.

44

RP-HPLC
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Figure 29. RP-HPLC traces demonstrating the changes in product conversion
produced by including 10 mM DTT during heat treatment of SrtApneu batch 3.
Reactions were incubated at room temperature for 24 hrs before analysis. Heattreatment of SrtApneu for 22 hours at 37 °C increased substrate processing when
10 mM DTT was added compared to samples which were not heated or heated
without 10 mM DTT. Unfortunately, incubation of SrtApneu for 1 week with DTT at
37 °C resulted in samples with diminished activity when compared to shorter
heating times.
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Figure 30. (A) Native PAGE gel demonstrating the effects of DTT on 22 hour
incubations of batch 3 SrtApneu at 37 °C. (B) Native PAGE gel demonstrating the
effects of DTT on 7 day incubations of batch 3 SrtApneu at 37 °C. Samples with
DTT are denoted in the lane labels above. DTT appears to increase the intensity
of the top band in the monomer doublet at the bottom of the gel, in addition to
increasing overall monomer concentration.
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Figure 31. RP-HPLC traces displaying the increase in SML activity with 10 mM
TCEP added to SE-FPLC purified monomeric SrtApneu the denaturing purification
after it was isolated. Reaction with TCEP was incubated 23 hrs at room
temperature and the reaction without TCEP was incubated 24 hrs at room
temperature before analysis.
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In an attempt to combine the incremental improvements gained by
enzyme refolding and the addition of TCEP, we ultimately settled on a revised
SrtApneu purification/refolding scheme in which TCEP was added to 1 mM in all
purification and storage buffers. First, SrtApneu was expressed at 37 oC, followed
by IMAC purification under denaturing conditions in the presence if 1 mM TCEP.
IMAC fractions were then rapidly diluted in non-denaturing buffer containing 1
mM TCEP, followed by an additional IMAC step to concentrate the enzyme.
Enzyme samples purified under these conditions had higher relative monomeric
concentration as compared to our original batch 2/3 materials that were neither
refolded nor treated with TCEP (Figure 32). TCEP addition also increased the
intensity of the upper band in the monomer doublet observed in native PAGE
gels of SrtApneu samples, which we presume to be the active component of these
enzyme preparations. Using SE-FPLC, enriched monomeric samples could be
easily isolated (Figures 32 and 33). After isolation, we were pleased to observe
that monomeric SrtApneu performed equally as well as the batch 1 positive control
in model SML reactions (Figure 34), where 95% conversion was observed for
the TCEP purified SrtApneu samples.
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Figure 32. (A) SDS-PAGE gel showing analysis of the purification steps of
SrtApneu with TCEP as a buffer component. The sample in lane 5 of this gel was
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2.2 Analysis of Potential Modes of SrtApneu Inactivation
Given that we were able to separate monomeric SrtApneu from oligomeric
SrtApneu, we next explored how the reactivity of oligomerized enzyme compared
to the monomer. Using oligomeric SE-FPLC fractions in model SML reactions,
we observed significantly less conversion of the peptide substrate when
compared to monomeric fractions from the same purification (Figure 35). SDSPAGE and native PAGE analysis of these reactions confirmed that total enzyme
content was identical between reactions, and further showed that the assembly
state of the enzyme was not altered by the presence of SML reaction
components. Overall, these results demonstrate that monomeric SrtApneu
provided the best in vitro reactivity, while preparations enriched in enzyme
oligomer were significantly less successful.
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Figure 35. (A) RP-HPLC traces demonstrating the variability in reactivity
between monomeric (blue) and oligomeric (green) preparations of TCEP purified
SrtApneu. After 7 hours of incubation at room temperature, the reaction containing
monomer reached 88% conversion, where as the oligomer reaction reached only
58% conversion. (B) Equimolar loading of samples from the SrtApneu catalyzed
peptide modification reactions in (A) separated through polyacrylamide gel
electrophoresis. Gel (1) contains SDS and gel (2) does not. Identical samples
were loaded in the lanes of each gel. Boxed lanes correspond to samples from
reactions in HPLC traces of the same color at left.
With the knowledge that reducing conditions improved the activity of our
SrtApneu preparations, we decided to evaluate the possibility of the active site
cysteine oxidation to sulfenic acid, which has been observed in SrtApyogenes
previously75. Commercially available, highly selective probes for sulfenic acid
residues can be used to evaluate this type of oxidation in protein samples102, 103
(Figure 36). For this purpose, batch 3 SrtApneu was buffer exchanged into
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HEPES buffer for the labeling reactions. A 10x molar excess of the sulfenic acid
probe NO2-alkyne was added to these samples. After 24 hours of incubation at
room temperature, positive control reactions assembled with 1.5 eq of H2O2 to
batch 3 SrtApneu yielded an uncharged mass of 20427 Da upon deconvolution of
the mass spectrum from the single peak in the sample (Figure 37). This exactly
matches the expected mass of 20427 Da for NO2-alkyne combined with SrtApneu.
The mass of SrtApneu was also found in the sample. Deconvolution of the mass
spectrum from the single peak in the experimental reaction did not display the
expected uncharged mass for the NO2-alkyne+SrtApneu adduct for batch 3
SrtApneu. This result suggests that batch 3 samples, which function poorly in
sortase mediated ligation reactions, do not suffer from sulfenic acid modifications
to the active site cysteine.
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Figure 36. (A) Structure of sulfenic acid probe NO2-alkyne used in the batch 3
SrtApneu labeling reactions. (B) Mechanism of addition to a potential sulfenic acid
modification in the active site of SrtApneu by the NO2-alkyne probe. This forms a
stable thioether bond, allowing the change in mass to be easily recognized by
mass spectrometry.
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Figure 37. (A) Mass spectrum of the single peak found in labeling reactions for
an unmodified sample of batch 3 SrtApneu after 24 hours of incubation with the
NO2-alkyne sulfenic acid probe. (B) Deconvolution of the mass spectrum in (A),
which returns an uncharged mass of 20144 Da as the major species, matching
that of unmodified SrtApneu. (C) Mass spectrum of the single peak found in
labeling reactions for a sample of batch 3 SrtApneu oxidized with 1.5 eq of H2O2
and incubated for 24 hours with the NO2-alkyne sulfenic acid probe. (D)
Deconvolution of the mass spectrum in (C) which shows two uncharged species
in the sample. One species represents unmodified SrtApneu (20145 Da) and the
other represents SrtApneu with the conjugated sulfenic acid probe NO2-alkyne
(20427 Da).
2.3 Conclusions and Future Directions.
This section detailed the progress from inactive samples of SrtApneu to fully
active samples of the enzyme. After evaluation of inactive SrtApneu samples
showed a high degree of oligomerization, we began exploring methods of
reducing the assembled forms of the enzyme. While heating samples of purified
SrtApneu returned activity to the samples and removed most of the oligomerized
enzyme, we believed more efficient procedures could be developed to achieve
the same result. By adding a denaturing step to the purification, we were able to
decrease some oligomerization in the SrtApneu samples. SE-FPLC purification of
SrtApneu after disassembly of oligomers proved to be an effective method to
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produce monomeric enzyme stocks. While we expected this to improve the
catalytic activity of the preparations, activity was only regained after addition of
the reducing agent TCEP to the purification buffer. The addition of TCEP to the
total purification also improved the monomer:oligomer ratio in the samples, which
afforded more available monomer for isolation by SEC. This purification
procedure has now consistently yielded active batches of enzyme over multiple
expressions in the lab.
As noted previously, inclusion of a reducing agent in the SrtApneu buffers
modifies the intensity of an interesting doublet that appears in monomer region of
native PAGE gels. Previously, SrtApyogenes has been shown to have an altered
conformation upon oxidation of the active site cysteine to sulfenic acid.75 We
hypothesize that reducing conditions reverse some form of oxidation in SrtApneu,
which ultimately leads to differences in protein conformation. Both oxidized and
unoxidized forms of the protein could be present in solution, creating two
alternative conformers which would appear as separate bands in native PAGE
analysis. Additionally, based on the observation that reducing conditions diminish
the presence of oligomerized SrtApneu in solution, oxidation of the enzyme may
facilitate a conformation that is more susceptible to interactions with other
enzyme units in solution.
This thesis also marks the first account of oligomerized SrtApneu, along
with the first attempts to understand the cause and dissolution of the assembled
enzyme. The oligomerization of this SrtA homolog appears to be driven by highly
54

favorable interactions as determined by dilution experiments of these samples,
where no effect on oligomer concentration in solution was observed.
Interconversion between the dimer and monomer states of the enzyme appears
to have a high activation barrier, as it can only be disrupted by heating or
complete unfolding of the enzyme samples. Further, recovered monomeric
SrtApneu does not appear to rapidly re-oligomerize, also supporting the hypothesis
of a high activation barrier between the two states. Hypothetically, this behavior
could be attributed to domain swapping of SrtApneu monomers, evidence of which
comes from the structure of SrtApneu in a domain swapped conformation (PDB ID:
4O8L).
Three dimensional domain swapping is an interaction between two or
more identical protein monomers, where one or more domains or segments of
the monomers rotate out of the core structure and take the place of the same
amino acids in the opposite monomer.104 This interaction generally results in
identical interactions in both the closed monomer and domain swapped forms of
the proteins, but may also result in additional favorable interactions within the
domain swapped oligomers.104 In vivo, the open state that propagates
oligomerization is most likely generated when monomers are transiently exposed
to denaturing conditions, such as an acidic compartment within the cell.104 The
open monomers become free to form domain swapped interactions, which
creates the oligomerized forms of the protein. The process of converting between
either monomer or oligomer most likely has a high energy barrier, as favorable
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contacts must be broken to rotate protein domains out of the core structure.104
This allows for different states of the same protein to be present in solution.
Domain swapping has been simulated in vitro to afford not only dimeric
proteins,105 but also trimeric106, 107 and higher order107, 108 assembly states, which
suggests this phenomenon could produce the full range of oligomers seen in
samples of SrtApneu. These observed qualities of domain swapped proteins, in
addition to the domain swapped structure of SrtApneu, align with the data
presented in this thesis, and suggests that SrtApneu undergoes domain swapping
to form oligomerized enzyme. It would be beneficial to perform experiments
probing the dissociation constant of the monomer-dimer equilibrium, as these
could aide our understanding of the strength of the association between
monomers. Additionally, more rigorous analysis of alternative purification
conditions could be done to aide in our understanding of the mechanism of
domain swapping in SrtApneu, while also potentially simplifying purification of the
enzyme.
Future directions for this aspect of the project revolve around
crystallization of the monomeric preparations of SrtApneu. While trials towards this
have already been undertaken, more work is needed to develop the conditions
necessary for crystal growth.
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Chapter 3. Design and Synthesis of Ketomethylene-based
Substrate Analogs
3.1 Design of Ketomethylene Isosteres
Concurrent with our efforts to produce reliable preparations of active
SrtApneu suitable for structural characterization, we have also undertaken the
synthesis of substrate mimics that can be covalently anchored in the enzyme
active site. To this end, we have designed substrate analogs in which the scissile
amide bond of standard sortase substrates is replaced with a non-cleavable
ketomethylene dipeptide isostere (Figure 38).
We anticipated that ketomethylene isosteres of SrtApneu substrates would
serve as non-cleavable analogs for obtaining a structure of the substrate bound
state. The proposed ketomethylene analogs for this purpose have been
previously used as potent inhibitors of serine proteases,109 which share
mechanistic characteristics with sortases. We propose that the inserted ketone
will be able to form a covalent bond with the active site cysteine which will be
further stabilized by the remaining contacts present in standard sortase
substrates. The synthetic processes laid out here allow for variability in the
substitution present at either site in the ketomethylene-linked dipeptide. Further,
the methods for developing these molecules allow for the production of
fluorenylmethyloxycarbonyl (Fmoc) protected N-termini109, 110, affording products
ready for incorporation into peptides via solid phase synthesis.
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3.2 Preliminary Ketomethylene Analog Synthesis and Testing
To evaluate the ability of a ketomethylene-linked peptide interacting with
the active site of SrtApneu, we first synthesized a substrate analog incorporating
commercially available 5-aminolevulinic acid. While this unit was not anticipated
to be optimal with respect to enzyme recognition due to the lack of sidechains in
position 4 and 5 of the substrate mimic, we elected to start with this compound as
a proof of concept study. As described by Rogers et al.,111 synthesis began with
solution-phase acylation of 5-aminolevulinic acid with the N-hydroxysuccinamide
ester of Fmoc-Ala-OH (Fmoc-Ala-OSu) to produce an Fmoc-protected
ketomethylene tripeptide analog of Ala-Gly-Gly, hereafter referred to as FmocA[G(keto)G]. This material was then used in solid-phase peptide synthesis
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(SPPS) to generate a full size substrate analog (1).112 The identity of 1 was
verified by ESI-MS, the material was purified to homogeneity by RP-HPLC, and
the peptide was lyophilized prior to use (Figure 39).
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Figure 39. Synthesis and analysis of the preliminary ketomethylene substrate
analog using the AG(keto)G block to install a non-cleavable linkage between the
4th and 5th residues.
With purified 1 in hand, we proceeded to test its inhibitory activity using a
model SML reaction. Specifically, a heat-treated stock of SrtApneu with
demonstrated SML activity was combined with a standard Abz-LPATA-GK(Dnp)
substrate, L-alanine amide, and varying concentrations of ketomethylene analog
1 (Figure 40). The nucleophile L-Alanine amide was used in these reactions to
avoid the oxime formation observed with hydroxyamines and ketones, as would
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be expected for the model reaction system used in Chapter 2 of this thesis.
Analysis via RP-HPLC suggested that analog 1 was able to act as an inhibitor,
reducing reaction conversion at as low as 0.1 eq in relation to the Abz-LPATAGK(Dnp) substrate. Reaction progress was diminished by less than 50% at 1 eq
of inhibitor, and reached as little as 30% relative conversion at 5 eq. Aside from
the single expected peak from the inhibitor itself, no additional peaks developed
when the inhibitor was added, demonstrating that it was not being cleaved by the
enzyme. Overall, these data indicated that ketomethylenes can serve as noncleavable isosteres in SML, which in turn could be useful for structural
characterization of enzyme/substrate complexes.

SrtApneu

Abz-LPATAG-K(Dnp)

L-Ala amide
+/- 1

Abz-LPATA-NH2 +

AG-K(Dnp)
1

Abz-LPATAG-K(Dnp)

Realtive Reaction Conversion

1
Absorbance (330 nm)

AG-K(Dnp)

Elution time (min)

5

0.5

0
0

0.1

0.25

0.5

1

2.5

5

Equivalents of 1 relative to Abz-LPATAG-K(Dnp)

Figure 40. RP-HPLC analysis for the inhibition of transpeptidation by
ketomethylene substrate analog 1. These reactions were assembled with
undiluted, 7 day heat-treated SrtApneu and allowed to incubate at room
temperature for 24 hrs before quenching with N-ethylmaleimide (NEM) for
analysis by HPLC.
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3.3 Second Generation Design of Ketomethylene Substrate Analogs
Having successfully shown that 1 was able to impede an in vitro SML
reaction, we next sought to design derivatives with substituents that mimic the
side chains of position 4 and 5 in the sortase substrate motif. Ideally, these
substituents would match the side chains of threonine and alanine residues for
optimal structural overlap with the known LPATA substrate of SrtApneu. However,
for synthetic ease we opted to focus on simple methyl groups, which would mirror
the side chains of alanine residues. While it was known from previous work in our
group that alanine was well tolerated in position 5 (see Figure 4), we wanted to
verify that alanine was accepted at position 4 or in combination with alanine at
position 5. To test this, peptide substrates displaying LPATAG, LPAAGG, and
LPAAAG were prepared via SPPS and tested in model SML reactions. As shown
in Figure 41, all variants were accepted by SrtApneu, however, the LPAAGG (53%
conversion) and LPAAAG (20% conversion) substrates were not processed to
the same extent as LPATAG (88% conversion). Nonetheless, these results
suggested that simple methyl groups in positions 4 and 5 should suffice for
enzyme recognition. Based on these results, two additional ketomethylene-linked
peptide isosteres were designed to serve as substrate analogs of LPAAG (2) and
LPAAA (3) (Figure 42).
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Abz-LPATAG-K(Dnp)

SrtApneu
H2N-OH
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Abz-LPAT-NHOH + AG-K(Dnp)
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Figure 41. Analytical RP-HPLC traces showing the variable activity of SrtApneu
with substrates differing from its preferred sequence of LPATA. These reactions
were incubated for 24 hrs at room temperature using a monomeric fraction of
SrtApneu from FPLC purification with TCEP.
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Figure 42. Structures of the next generation of ketomethylene-based substrate
analogs for SrtApneu. 2 represents the ketomethylene analog of LPAAG and 3
represents the analog of LPAAA. These pseudopeptides will include substitution
at the amino acid positions surrounding the non-cleavable ketomethylene linkage
used to replace the scissile peptide bond.
3.4 Progress Toward Synthesis of Substituted Ketomethylene Isosteres
To access structures 2 and 3, we began with a procedure from Budnjo et
al.109 towards synthesizing the ketomethylene linked dipeptide isosteres A(keto)G
and A(keto)A to be incorporated into full substrate analogs. As shown in Scheme
1, our proposed synthetic process involved addition of the lithium enolate of tbutyl acetate to carbonyldiimidazole (CDI)-activated Fmoc-Ala-OH. The resulting
β-ketoester (5) would then serve as a nucleophile in a stereospecific substitution
of triflates derived from either t-butyl R-lactate (4a) or t-butyl glycolate (4b).
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Treatment with TFA was anticipated to remove the t-butyl ester protecting
groups, followed by in situ decarboxylation to generate the desired keto
methylene building blocks 7a or 7b.
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Scheme 1. Overview of the synthetic scheme from Budnjo et al.109 using an
Fmoc-protected amino acid starting material.
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Efforts to execute the plan in Scheme 1 began with lithium enolate
addition to CDI-activated Fmoc-Ala-OH following the reported protocol from
Budnjo et al. However, in our hands this approach repeatedly failed to generate
the desired product, instead leading to Fmoc deprotection. An alternative
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procedure from Mathieu et al.110 involving catalytic 4-dimethylaminopyridine
(DMAP) to activate the amino acid and excess t-butyl acetate to generate the
enolate, was substituted for the procedure by Budnjo et al. (Scheme 2) which
enabled us to synthesize the desired product 5 in 27% yield. With the ketoester
in hand, we then prepared triflates 4a (72% yield) and 4b (73% yield) using triflic
anhydride and 2,6-lutidine (Scheme 3) according to the procedure from Budnjo
et al.
O
HO

OtBu
R

2,6lutidene
Tf2O
DCM
0o C

O
TfO

OtBu

R
4a (R= CH3) or 4b (R= H)
72% yield
73% yield

Scheme 3. Synthesis of triflate compounds from t-butyl esters with varying
substitution.
Having successfully synthesized the triflate compounds, we attempted the
SN2 substitution using NaH to deprotonate the ketoester (Scheme 4) also
described by Budnjo et al. Despite repeated attempts using varying equivalents
of NaH and triflate 4a, the reaction proved entirely unsuccessful, with either
Fmoc deprotection or unreacted starting material being the only consistent
results observed. Since no product was observed, we decided to attempt the final
step of the synthetic scheme with triflate 4b. Since this compound lacks the extra
methyl group of 4a, we believed it would behave as a better electrophile due to
its relative lack of steric hindrance around the reactive center. This compound
still failed to produce significant amounts of product 6b, and attempts to improve
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reaction turnover by including slight excesses of NaH only resulted in greater
deprotection of the Fmoc-Ala t-butyl ketoester.
O
i) NaH (excess)
THF
OtBu -5o C

FmocHN

OtBu
OtBu

FmocHN

O

O
5

ii) 4a or 4b
-5o C to RT

O

O

6a or 6b
Not observed
(Mostly Fmoc deprotection)

Scheme 4. Synthetic process to generate the fully protected ketomethylene
After these many failed attempts at using the Fmoc-protected starting
material, we elected to begin the synthesis with tert-butyloxycarbonyl protected
Ala-OH (Boc-Ala-OH), which was anticipated to retain the Boc protecting group
throughout each set of reaction conditions. We refrained from this initially
because it involved the deprotection and reprotection of the N-terminus of the
ketomethylene, however, we determined that an extra step in the synthesis was
more desirable than being unable to obtain the desired product.
The synthetic scheme to generate the desired A(keto)G dipeptide isostere
starting with a Boc protected amino acid is described in Scheme 5. Boc-Ala-OH
was combined with the lithium enolate of t-butyl acetate to generate the Bocprotected ketoester 8 (Scheme 6) which was easily purified from the extracted
reaction by flash column chromatography (FCC) in 72% yield. Triflates were
synthesized from the procedure used previously and used without further
purification.
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Scheme 5. Overall synthetic scheme to produce Fmoc-protected ketomethylene
dipeptide isosteres using Boc amino acids as starting materials.
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Scheme 6. Synthesis of the Boc-protected ketoester

The final step of this synthesis was achieved by deprotonating ketoester 8
using excess NaH (Scheme 7) and combining the resulting mixture with triflates
4a or 4b. Initial attempts at this reaction using triflate 4b failed without the
addition of excess NaH, where substantial amounts of starting materials
remained unreacted even after 24 hours of stirring. After determining the
necessity for excess NaH, the reaction succeeded and the product 9b was
easily purified from the reaction mixture. Unfortunately, 1H nuclear magnetic
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resonance (NMR) spectroscopy of this product was too convoluted to accurately
assign peaks, however, LC-ESI-MS was able to confirm the mass of the Na+
adduct of this material.
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Scheme 7. Synthesis of the fully protected Boc-ketomethylene.

After removal of the Boc and t-butyl groups with trifluoroacetic acid (TFA)
and in situ decarboxylation to afford the deprotected ketomethylene 10b,
reprotection of the N-terminus was carried out using Fmoc-OSu (Scheme 8). The
use of excess diisopropylethylamine (DIPEA) was necessary to maintain the
deprotonated state of the ketomethylene, as we were unable to completely
remove the TFA from the samples, which we anticipated consumed much of the
base before it was able to increase the pH of the reaction mixture. The mass of
the N-protected ketomethylene 11b was confirmed by mass spectrometry of the
crude mixture. A 1H NMR spectrum was also obtained (see Appendix I), but was
not analyzed due to contaminants, as these made it impossible to confidently
assign peaks.
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Scheme 8. Synthesis of disubstituted Fmoc protected ketomethylene

Current efforts on this project involve the producing larger quantities of
11b, followed by incorporation of the material into SPPS procedures to generate
the aforementioned substrate analog 2. After synthesis of this analog, analysis
on its inhibitory capacity with SrtApneu will be performed, which we anticipate to
be more effective than that displayed by the preliminary substrate analog 1.
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4. Experimental
Protein Expression and Purification
Full sequence of SrtApneu protein used in this study:
MESSHHHHHHAVLTSQWDAQKLPVIGGIAIPELEMNLPIFKGLDNVNLFYGAGT
MKREQVMGEGNYSLASHHIFGVDNANKMLFSPLDNAKNGMKIYLTDKNKVYTY
EIREVKRVTPDRVDEVDDRDGVNEITLVTCEDLAATERIIVKGDLKETKDYSQTS
DEILTAFNQPYKQFY
Expression and purification of SrtApneu batches 1 and 3. The SrtApneu
expression vector was obtained by commercial gene synthesis in a pJ414
expression vector from DNA2.0 (Menlo Park, CA). The plasmid containing
SrtApneu was transformed into BL21 (DE3) chemically competent E. coli by heat
shock. Following addition of 1 mL Luria-Bertani (LB) broth, the cells were
incubated for 1 hour at 37 oC with shaking. Cells were the plated on LB-agar
plates containing 100 µg/mL ampicillin, and incubated overnight at 37 oC. A
single isolated colony was selected and used to inoculate 50 mL of LB broth
(containing 100 µg/mL ampicillin), which was then placed in a 37 oC shaking
incubator to grow overnight. Roughly 30 mL of this starter culture were then
added to 1 L of LB broth (containing 100 µg/mL ampicillin) to initiate large-scale
growth. This culture was allowed to grow to an OD600 reading of 0.7-0.8 at 37 oC
in a shaking incubator. Protein expression was then induced by the addition of
isopropyl-β-D-1-thiogalactopyranoside (IPTG) to a final concentration of 1 mM.
Cells remained at 37 oC with shaking for 3 hours to express SrtApneu, and were
then isolated by centrifugation at 10000xg. The cell pellets were then
resuspended in 30 mL lysis buffer (50 mM Tris pH 8.0, 150 mM NaCl, 0.5 mM
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EDTA), treated with lysozyme at a final concentration of 10 mg/mL, and
incubated at room temperature for 1 hour. This mixture was sonicated for 2, 30
second intervals at 50% output and the lysate was then clarified by centrifugation
at 20000xg. This clarified lysate was added to a 5 mL His-Bind (Thermo-Fisher)
Ni-NTA column equilibrated in wash buffer (20 mM Tris pH 8.0, 150 mM NaCl, 20
mM imidazole). Bound protein was further washed with 10 column volumes of
wash buffer, then eluted in two, 1 column volume aliquots of elution buffer (20
mM Tris pH 8.0, 150 mM NaCl, 300 mM imidazole). These preparations were
dialyzed against dialysis buffer (20 mM Tris pH 8.0, 150 mM NaCl) to remove
imidazole. Glycerol was added to 10% v/v before the samples were stored at -80
o

C. Collected fractions were analyzed by native and SDS-PAGE. The activity of

these samples was evaluated by model sortase-mediated ligation (SML)
reactions with the known substrate LPATA. Were described, FPLC analysis of
these samples was performed Samples of SrtApneu were subjected to various
incubation temperatures for various times before purification and analysis on an
NGC FPLC system (Bio-Rad) by size-exclusion chromatography using an Enrich
SEC 70 column (Bio-Rad) with 50 mM Tris pH 8.0, 150 mM NaCl buffer as the
eluent at 0.5 or 0.75 mL/min. Variable temperature expressions described in
Chapter 2 were carried out by this procedure, except during expression, where
the temperature was adjusted to 16 or 25 °C.
Expression and purification of SrtApneu batch 2. The SrtApneu expression
vector was obtained by commercial gene synthesis in a pJ414 expression vector
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from DNA2.0 (Menlo Park, CA). The plasmid containing SrtApneu was transformed
into BL21 (DE3) chemically competent E. coli by heat shock.. Following addition
of 1 mL LB broth, the cells were incubated for 1 hour at 37 oC with shaking. Cells
were the plated on LB-agar plates containing 100 µg/mL ampicillin, and
incubated overnight at 37 oC. A single isolated colony was selected and used to
inoculate 50 mL of LB broth (containing 100 µg/mL ampicillin), which was then
placed in a 37 oC shaking incubator to grow overnight. Roughly 30 mL of this
starter culture were then added to 1 L of LB broth (containing 100 µg/mL
ampicillin) to initiate large-scale growth. This culture was allowed to grow to an
OD600 reading of 0.7-0.8 at 37 oC in a shaking incubator. Protein expression was
then induced by the addition of IPTG to a final concentration of 1 mM. Cells
remained at 37 oC with shaking for 3 hours to express SrtApneu, and were then
isolated by centrifugation at 6000xg. The cell pellets were then resuspended in
30 mL lysis buffer (50 mM Tris pH 8.0, 150 mM NaCl, 0.5 mM EDTA), treated
with lysozyme at a final concentration of 10 mg/mL, and incubated at RT for 1
hour. This mixture was sonicated for 2, 30 second intervals at 50% output and
the lysate was then clarified by centrifugation at 18000xg. This clarified lysate
was added to 5 mL of His-Bind (Thermo-Fisher) Ni-NTA resin in a conical tube
and imidazole was added to 20 mM before the contents were mixed for 30 min at
room temperature. The slurry was centrifuged at 700xg for 2 min and the
supernatant removed. The resin pellet was resuspended in 25 mL of wash buffer
(20 mM Tris, pH 8.0, 150 mM NaCl, 20 mM imidazole) and transferred to an
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empty column. After settling, the wash buffer was drained to the resin bed and 25
mL of wash buffer was passed through the column. Bound protein was then
eluted in two, 5 mL aliquots of elution buffer (20 mM Tris pH 8.0, 150 mM NaCl,
300 mM imidazole). To further purify the eluted protein, elution 1 of the initial
purification was diluted 10-fold with dilution buffer (20 mM Tris, pH 8.0, 150 mM
NaCl) and recirculated through a 5 mL Ni-NTA column. The bound protein was
further washed with 10 mL of wash buffer and eluted in 3, 5 mL portions of
elution buffer. The loading flowthrough of this purification was also
reconcentrated using a 5 mL Ni-NTA column. After loading, the bound protein
was washed with 15 mL wash buffer and and eluted in two, 5 mL aliquots of
elution buffer. These preparations from the 2nd and 3rd purification steps were
dialyzed against dialysis buffer (20 mM Tris pH 8.0, 150 mM NaCl) to remove
imidazole. Glycerol was added to 10% v/v before the samples were stored at -80
o

C. Collected fractions were analyzed by native and SDS-PAGE. The activity of

these samples was evaluated by model sortase-mediated ligation (SML)
reactions with the known SrtApneu known substrate LPATA.
SrtApneu expression, non-reducing/denaturing purification and refolding. A
50 uL aliquot of BL21(DE3) cells in 50% glycerol containing the plasmid for
SrtApneu was added to 50 mL of LB broth containing 100 µg/mL ampicillin and
incubated with shaking at 37 oC overnight. Roughly 30 mL of culture were then
added to one 1 L of LB broth containing 100 µg/mL ampicillin to initiate largescale growth. This culture was allowed to grow to an OD600 reading of 0.7-0.8 at
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37 oC in a shaking incubator before induction with 1 mM IPTG. Cells remained at
37 oC with shaking for three hours to express SrtApneu, and were then isolated by
centrifugation at 6000xg. Cell pellets were resuspended in 30 mL denaturing lysis
buffer (50 mM Tris pH 8.0, 150 mM NaCl, 0.5 mM EDTA, 8 M urea). The
resuspended cells were sonicated for 2, 30 second intervals at 50% power output
and the lysate was clarified by centrifugation at 18000xg. This clarified lysate was
added to a 5 mL His-Bind resin (Thermo-Fisher) column pre-equilibrated in
denaturing wash buffer (50 mM Tris pH 8.0, 150 mM NaCl, 20 mM imidazole, 8
M urea). Bound protein was washed with 10 column volumes of wash buffer and
then eluted in two, 1 column volume portions of denaturing elution buffer (50 mM
Tris pH 8.0, 150 mM NaCl, 300 mM imidazole, 8 M urea). The first eluted fraction
was then rapidly diluted by addition to a 100x volume of dilution buffer (50 mM
Tris pH 8.0, 150 mM NaCl). This material was then recirculated through a 5 mL
Ni-NTA column equilibrated in wash buffer (50 mM Tris pH 8.0, 150 mM NaCl, 20
mM imidazole). Bound protein was further washed with 10 column volumes of
wash buffer, then eluted in two 1 column volume aliquots of elution buffer (50 mM
Tris pH 8.0, 150 mM NaCl, 300 mM imidazole). Collected fractions were
analyzed by native and SDS-PAGE. SrtApneu monomer was further purified on an
NGC FPLC system (Bio-Rad) by size-exclusion chromatography using an Enrich
SEC 70 column (Bio-Rad) with 50 mM Tris pH 8.0, 150 mM NaCl buffer as the
eluent at 0.5 mL/min. Monomeric protein fractions were pooled, and if necessary,
concentrated using centrifugal concentrators. The activity of these samples was
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evaluated by model sortase-mediated ligation (SML) reactions with the known
substrate LPATA. These samples were stored at 4 oC or -20 oC.
SrtApneu expression, reducing/denaturing purification and refolding. The
optimized procedure for the expression and purification of SrtApneu is identical to
that for the non-reducing/denaturing purification described above, with the
exception of 1 mM TCEP being included in all buffers used.
Evaluation of protein concentration. UV-vis spectroscopy for determining
concentrations of the prepared samples was performed on a NanodropTM ND1000 spectrophotometer (Thermo Scientific) at 280 nm using 17,440 M-1cm-1 as
the estimated molar extinction coefficient from analysis of the protein sequence
by ExPasy ProtParam.
Protein LC-ESI-MS analysis. Liquid chromatography electrospray
ionization mass spectrometry (LC-ESI-MS) was performed using a Dionex
Ultimate 3000 HPLC system (Thermo Scientific) connected to an expression L
high performance compact mass spectrometer (Advion, Inc.) through analytical
scale separations using a Phenomenex Kinetex 2.6 µm, 100 Å C4 column (2.0 x
100 mm) with the method (Method A): MeCN (0.1% formic acid)/95% H2O, 5%
MeCN (0.1% formic acid) mobile phase. Flow rate = 0.3 mL/min. Gradient = 10%
MeCN (0.0-0.5 min), 10% MeCN to 90% MeCN (0.5-6.0 min), hold 90% MeCN
(6.0-7.0 min), 90% MeCN to 10% MeCN (7.0-7.1 min), re-equilibrate to 10%
MeCN (7.1-10.0 min). Data analysis was done in Advion Data Express software
version 3.0. Mass spectrum deconvolution was achieved through a max entropy
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goodness of fit algorithm to determine uncharged masses of samples.

Analysis of SrtApneu Transpeptidation Activity
Evaluation of enzymatic activity with various peptides containing the
fluorophore-quencher pair 2-aminobenzoyl (Abz) and 2,4-dinitrophenol (Dnp)
were carried out at room temperature with the concentrations shown in the table
below for the model sortase mediated ligation reactions. Specific additives are
noted where necessary within the presentation of the data. Reactions were
prepared by combining all components shown in Table 4 except sortase, which
was added to initiate the reaction. Conversion was analyzed by UV/VIS analysis
of analytical RP-HPLC using a Dionex Ultimate 3000 HPLC system (Thermo
Scientific) with a Phenomenex Kinetex 2.6 µm, 100 Å C18 column (3.0 x 100
mm) with the method (Method B): MeCN (0.1% TFA)/H2O (0.1% TFA) mobile
phase. Flow rate = 0.7 mL/min. Gradient = 10% MeCN (0.0-0.5 min), 10% MeCN
to 90% MeCN (0.5-6.0 min), hold 90% MeCN (6.0-7.0 min), 90% MeCN to 10%
MeCN (7.0-7.1 min), re-equilibrate to 10% MeCN (7.1-10.0 min).
Percent conversion was calculated by dividing the area of the product
peak by the addition of total 2,4-DNP containing reactant and product peak areas
at 330 nm.
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Table 2. Reaction conditions for sortase mediated ligation. Water was added to
50 uL total reaction volume unless otherwise noted.
Stock Solution
Reaction Concentration
Buffer (500 mM Tris, pH 7.5, 150 mM
NaCl)

50 mM Tris, pH 7.5, 150 mM NaCl

Substrate (1:1 DMSO/Water) (0.5-4 mM)

40 or 100 µM

Nucleophile (Water) (10 mM)

10 mM

SrtApneu (50-300 µM)

10 µM

Peptide Synthesis
All chemicals were obtained from commercial sources and were used
without further purification. Reactions were performed in flame-dried glassware
under argon atmosphere. HPLC purification and analysis was performed using a
Dionex Ultimate 3000 HPLC system. LC-ESI-MS was performed with API 2000
Triple Quadrupole mass spectrometer (Applied Biosystems) and an Agilent 1100
HPLC system equipped with a Phenomenex Aeris Widepore 3.6 µm 200 Å XBC8 column (4.6 x 150 mm). All samples were analyzed using the following
method (Method C): H2O (0.1% formic acid) / organic (95% MeCN, 5%
isopropanol, 0.1% formic acid) mobile phase. Flow rate = 1.25 mL/min. Gradient
= 10% organic (0.0-1.0 min), 10% organic to 90% organic (1.0-10.0 min).
Analytical separations for UV/vis analysis were performed with a
Phenomenex Kinetex 2.6 µm, 100 Å C18 column (3.0 x 100 mm) with the method
(Method B): MeCN (0.1% TFA)/H2O (0.1% TFA) mobile phase. Flow rate = 0.7
mL/min. Gradient = 10% MeCN (0.0-0.5 min), 10% MeCN to 90% MeCN (0.5-6.0
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min), hold 90% MeCN (6.0-7.0 min), 90% MeCN to 10% MeCN (7.0-7.1 min), reequilibrate to 10% MeCN (7.1-10.0 min).
Semi-preparative separations for purification of peptides were performed
with a Phenomenex Luna 5 µm 100 Å C18 column (10 x 250 mm) fitted with a
Phenomenex SecurityGuard SemiPrep Guard cartridge (10 mm ID). Purification
separations were carried out with the one of the following methods: (Method D):
MeCN (0.1% TFA)/H2O (0.1% TFA) mobile phase. Flow rate = 0.5 to 4.0 mL/min
(0.0-2.0 min), hold 4.0 mL/min (2.0-17.01 min), 4.0 to 0.5 mL/min (17.01-19.0
min). Gradient = 20% MeCN (0.0-2.0 min), 20% MeCN to 90% MeCN (2.0-15.0
min), hold 90% MeCN (15.0-17.0 min), 90% MeCN to 10% MeCN (17.0-17.01
min), re-equilibrate to 10% MeCN (17.01-19.0 min) or (Method E): MeCN (0.1%
TFA)/H2O (0.1% TFA) mobile phase. Flow rate = 0.5 to 4.0 mL/min (0.0-2.0 min),
hold 4.0 mL/min (2.0-17.01 min), 4.0 to 0.5 mL/min (17.01-19.0 min). Gradient =
30% MeCN (0.0-2.0 min), 30% MeCN to 60% MeCN (2.0-15.0 min), 60 to 90%
MeCN (15.0-15.01 min), hold 90% MeCN (15.01-17.0 min), 90% MeCN to 10%
MeCN (17.0-17.01 min), re-equilibrate to 10% MeCN (17.01-19.0 min)
Solid-phase peptide synthesis. Peptides were synthesized on a 0.1 mmol
scale using rink amide MBHA resin. Deprotection was achieved by washing with
20% piperidine/NMP (10 mL, 2x, 20 min) and was followed by washing with NMP
(10 mL, 3x, 10 min). To the deprotected resin, a mixture containing an Fmoc
protected amino acid (0.3 mmol), HBTU (0.3 mmol) and DIPEA solvated in NMP
was added, which was left to incubate for 1 hr-24 hrs at room temperature with
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shaking. Unreacted coupling components were removed and the resin washed
with NMP (10 mL, 3x, 10 min) before repetition of this process to couple all
amino acids. Acetyl capping of the N-terminus was achieved by combining acetic
anhydride (0.3 mmol), DIPEA, and NMP, which was added to the resin to couple
for 2 hrs. Each peptide generated as a substrate for SML reactions contained the
2-aminobenzoyl (Abz) and 2,4-dinitrophenyl (Dnp) fluorphore-quencher pair to
simplify analysis by UV/vis spectroscopy. Dnp was added as a conjugate to εamine of a lysine side chain [Fmoc-K(Dnp)]. After completion of the peptide, the
resin was washed with DCM (10 mL, 3x, 10 min) and incubated with cleavage
solution (9.5 mL TFA, 0.25 mL H2O, 0.25 mL TIPS) for 30 min (5 mL, 2x). The
cleaved peptide was collected and concentrated via rotary evaporation before
being precipitated into dry ice-cooled diethyl ether. The precipitate was
centrifuged at 5000xg for 5 min and the ether discarded to afford a peptide pellet,
which was dried under vacuum for 24 hrs. Peptides were solubilized by a mixture
of water and acetonitrile that was variable based on the amino acid composition.
Purification from this state was achieved by RP-HPLC with either method D or E
and the molecular mass of the peptides verified via LC-ESI-MS method C.
Peptides were lyophilized and resolubilized in 1:1 water/DMSO or DMSO to
produce stock solutions for use in reactions, which were further analyzed for
purity by HPLC analysis using method B. Concentrations were estimated by
UV/Vis spectroscopy on a NanodropTM ND-1000 spectrophotometer (Thermo
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Scientific) at 365 nm using the molar extinction coefficient 17,400 M-1cm-1 for the
Dnp chromophore.

Synthesis of Small Molecules
All chemicals were obtained from commercial sources and were used
without further purification. NMR spectra were collected with a Brüker Avance
spectrometer at 500 MHz for 1H. FID processing and figure generation was done
using Mestrelab MestReNova software version 10.0.2-15465. Reactions were
performed in flame-dried glassware under argon atmosphere. HPLC purification
and analysis was performed using a Dionex Ultimate 3000 HPLC system. LCESI-MS was performed with a Dionex Ultimate 3000 HPLC system connected in
line to an expression L high performance compact mass spectrometer (Advion,
Inc.). Analytical separations for MS analysis of synthetic products were achieved
with a Phenomenex Kinetex 2.6 µm, 100 Å C18 column (2.0 x 100 mm) with the
method (Method F): MeCN (0.1% formic acid)/95% H2O, 5% MeCN (0.1% formic
acid) mobile phase. Flow rate = 0.4 mL/min. Gradient = 5% MeCN (0.0-0.5 min),
5% MeCN to 90% MeCN (0.5-6.0 min), hold 90% MeCN (6.0-7.0 min), 90%
MeCN to 10% MeCN (7.0-7.1 min), re-equilibrate to 10% MeCN (7.1-12.0 min).
Ala-5-ALA synthesis. Fmoc-Ala-OSu (1.2 g, 3.0 mmol) and 5aminolevulinic hydrochloride (0.50 g, 3.0 mmol) were added to dry THF (40 mL)
and cooled to 0 oC. DIPEA (0.52 mL, 3.0 mmol) was dissolved in dry THF (20
mL) and then added dropwise to the stirred suspension across 120 minutes. The
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reaction was allowed to return to room temperature and stirred for 23 days after
which the mixture was filtered, concentrated by rotary evaporation and dissolved
into ethyl acetate (50 mL). The organic layer was washed with water (3x, 50 mL)
and extracted into 5% NaHCO3 (3x, 25 mL). The aqueous layer was then
collected and acidified with 1M HCl until no further precipitation occurred. This
heterogeneous mixture was then extracted with ethyl acetate (3x, 75 mL) and
dried over MgSO4. The solvent was removed by rotary evaporation to produce a
white solid which was used without further purification. IUPAC Name: (S)-5-(2((((9H-fluoren-9-yl)methoxy)carbonyl)amino)propanamido)-4-oxopentanoic acid
(0.72 g, 57% yield). 1H NMR (500 MHz, D6-DMSO): δ 12.10 (br. s, 1H), 8.13 (m,
1H), 7.88 (d, J = 7.6, 2H), 7.72 (t, J = 7.7, 2H), 7.55 (d, J = 7.7, 1H), 7.40 (t, J =
7.3, 2H), 7.32 (t, J = 7.5, 2H), 4.26-4.18 (m, 3H), 4.11-4.05 (m, 1H), 3.98-3.87 (m,
2H), 2.63 (t, J = 6.2, 2H), 2.39 (t, J = 6.5, 2H), 1.23 (d, J = 7.2, 3H).
Ketoester synthesis. Boc-Ala-OH (7.0 mmol) was dissolved in dry THF (20
mL), to which CDI (1.08 g, 7.7 mmol) was added under stirring in three portions,
resulting in bubble formation. Within five minutes of CDI addition, 5 mol% DMAP
was added to the reaction mixture. This was left to stir for one hour, during which
t-butyl acetate (4.1 mL, 28.7 mmol) was added dropwise to 1 M LiHMDS (28 mL,
28 mmol) in THF (28 mL) at -78 oC under stirring across 5-10 minutes. This
reaction was left to stir for 10-15 min at -78 °C, removed from cooling and stirred
at room temperature for 10 minutes, then cooled to -78 °C and stirred for 20
additional minutes before the activated amino acid was added dropwise at -78 °C
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across 10 minutes. The combined reaction was allowed to stir for 1.5 hrs at -78
°C before being quenched with 10% w/v citric acid (50 mL). The mixture was
extracted with ethyl acetate (2x, 30 mL), washed with sat. NaHCO3 (30 mL) and
sat. NaCl (3x, 30 mL) before being dried over MgSO4. After concentration by
rotary evaporation, the crude product was purified by flash column
chromatography (1:3 EtOAc/n-hexane) yielding the product as a white solid.
IUPAC Name: tert-butyl (S)-4-((tert-butoxycarbonyl)amino)-3-oxopentanoate
(1.44 g, 72% yield). 1H NMR (500 MHz, CDCl3): δ 5.19-5.09 (m, 1H), 4.42-4.32
(m, 1H), 3.49, 3.42 (ABq, JAB = 16, 2H), 1.46 (s, 9H), 1.44 (s, 9H), 1.35 (d, J =
7.2, 3H).
Triflate synthesis. To a solution of t-butyl R-lactate or t-butyl 2hydroxyacetate (5.0 mmol) in dry DCM (20 mL) was added 2,6-lutidine (0.87 mL,
5.0 mmol). The mixture was cooled to 0 °C and triflic anhydride (1.18 mL, 5.0
mmol) was added dropwise across 70 minutes, during which the color changed
to light red then orange. After stirring for 1 hour at 0 °C, the reaction mixture was
diluted with n-hexane (100 mL), washed with 1:3 1M HCl/sat. NaCl (3x, 50 mL),
and dried over MgSO4. The extract was concentrated by rotary evaporation and
dried under vacuum to afford the product as a red or orange oil which was used
without further purification.
IUPAC Name: tert-butyl (R)-2-(((Trifluoromethyl)sulfonyl)oxy)propanoate
(1.01 g, 73% yield). 1H NMR (500 MHz, CDCl3): δ 5.09 (q, J = 7.0, 1H), 1.66 (d, J
= 7.0, 3H), 1.50 (s, 9H). 1H NMR consistent with previously reported spectra.109
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IUPAC Name: tert-butyl 2-(((Trifluoromethyl)sulfonyl)oxy)acetate (0.96 g,
72% yield). 1H NMR (500 MHz, CDCl3): δ 4.78 (s, 2H), 1.51 (s, 9H).
Ketomethylene synthesis. Boc-Ala ketoester (0.50 g, 1.7 mmol) was
solvated in dry DCM (10 mL) and added dropwise to a stirred suspension of NaH
(60% in mineral oil, 0.21 g, 5.2 mmol) in dry THF (10 mL) at -5 °C. This mixture
was allowed to stir for 20 min, after which triflate (1.74 mmol) in dry THF (5 mL)
was added at -5 °C. The resulting contents were allowed to stir overnight at room
temperature before being quenched with 10% w/v citric acid (20 mL). The
quenched reaction was extracted with EtOAc (3x, 20 mL) washed with sat. NaCl
(60 mL), and dried over MgSO4 before being concentrated via rotary evaporation
to yield a yellow oil. This residue was purified by flash column chromatography
with 1:3 EtOAc/hexane and the desired product fractions identified, pooled, and
concentrated by rotary evaporation. This residue was solvated in 10% TFA/DCM
and allowed to stir overnight at room temperature. After concentrating the
resulting mixture by rotary evaporation, the residue was dissolved in DCM and
reconcentrated by rotary evaporation (3x) after which the remaining solvent was
removed in vacuo. Data for protected ketomethylene: IUPAC Name: di-tert-butyl
2-((tert-butoxycarbonyl)-L-alanyl)succinate LC-ESI-MS: m/z calculated (M+Na+):
424.5, observed: 424.3.
Fmoc protection. The vacuum dried deprotected ketomethylene was
dissolved in 1:1 water/MeCN (10 mL) and DIPEA (0.91 mL, 3 eq) was
administered to bring the solution to pH ~8. Fmoc-OSu (0.59 g, 1 eq.) was added
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and allowed to react for 24 hours before the addition of 10 mL of 1 M HCl, which
formed a precipitate. The reaction was extracted into EtOAc (3x, 10 mL), washed
with sat. NaCl (30 mL) and dried over MgSO4 before being concentrated under
rotary evaporation. The residue was solubilized in 1:1 EtOAc/n-hexane (0.1%
AcOH) and purified by flash column chromatography using 1:1 EtOAc/n-hexane
(0.1% AcOH) until the product began to elute, at which point 3:1 EtOAc/n-hexane
(0.1% AcOH) was used as the solvent. IUPAC Name: (S)-5-((((9H-fluoren-9yl)methoxy)carbonyl)amino)-4-oxohexanoic acid. LC-ESI-MS: m/z calculated
(M+Na+) 390.4, observed 390.1.

Inhibition of In vitro Transpeptidation Reactions.
Transpeptidation inhibition assays. Reactions for analysis of the
preliminary inhibitor substrate analog 1 were prepared from 7 day 37 °C heattreated batch 3 SrtApneu and incubated for 24 hours at room temperature before
quenching with N-ethylmaleimide. Reactions were prepared by combining all
components shown in Table 4 except sortase, which was added to initiate the
reaction. HPLC analysis was performed using a Dionex Ultimate 3000 HPLC
system, which allowed for monitoring by UV/Vis analysis of the separations using
a Phenomenex Kinetex 2.6 µm, 100 Å C18 column (3.0 x 100 mm) with the
method (Method B): MeCN (0.1% TFA)/H2O (0.1% TFA) mobile phase. Flow rate
= 0.7 mL/min. Gradient = 10% MeCN (0.0-0.5 min), 10% MeCN to 90% MeCN
(0.5-6.0 min), hold 90% MeCN (6.0-7.0 min), 90% MeCN to 10% MeCN (7.0-7.1
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min), re-equilibrate to 10% MeCN (7.1-10.0 min). Percent conversion was
calculated by dividing the area of the product peak by the addition of total 2,4DNP containing reactant and product peak areas at 330 nm.
Table 3. Reaction conditions for sortase mediated ligation inhibition assays.
Volume of components used are given in µL. Water was added to 50 uL total
reaction volume unless otherwise noted.
Reaction
Buffer (500 mM Tris,
pH 7.5, 150 mM NaCl)

1
5

2
5

3
5

4
5

5
5

6
5

7
5

SrtApneu (300 µM)

1.7

1.7

1.7

1.7

1.7

1.7

1.7

L-Alanine amide HCl
(100 mM)

5

5

5

5

5

5

0

Abz-LPATA-GK(Dnp)
(3.7 mM)

1.4

1.4

1.4

1.4

1.4

1.4

1.4

0.5

2.5

5

10

25

0

Ac0
K(Dnp)LPAG(keto)GAA
(1.0 mM)

Attempted detection of Sulfenic Acid Modification
Sulfenic acid labeling reactions. Batch 3 SrtApneu in HEPES buffer (20 mM
HEPES, 150 mM NaCl) was diluted to 50 µM before NO2-alkyne was added to
500 µM. For the positive control reaction with H2O2, SrtApneu in HEPES buffer was
diluted to 10 µM and H2O2 was added to 15 µM before NO2-alkyne was added to
100 µM. After mixing the solutions, they were allowed to stand for 24 hours at
room temperature before analysis by LC-MS Dionex Ultimate 3000 HPLC system
(Thermo Scientific) connected to an expression L compact mass spectrometer
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(Advion, Inc.) using a Phenomenex Kinetex 2.6 µm, 100 Å C4 column (2.0 x 100
mm) with the method (Method A): MeCN (0.1% Formic acid)/95% H2O, 5%
MeCN (0.1% Formic acid) mobile phase. Flow rate = 0.3 mL/min. Gradient =
10% MeCN (0.0-0.5 min), 10% MeCN to 90% MeCN (0.5-6.0 min), hold 90%
MeCN (6.0-7.0 min), 90% MeCN to 10% MeCN (7.0-7.1 min), re-equilibrate to
10% MeCN (7.1-10.0 min). Data analysis was done in Advion Data Express
software version 3.0. Mass spectrum deconvolution was achieved through a max
entropy goodness of fit algorithm to determine uncharged masses of samples
Table 4. Stock solutions and reaction concentrations of the components used in
sulfenic acid labeling reactions for SrtApneu. All unlabeled values are in µL. *
denotes the use of a 10 mM stock of NO2-alkyne probe, prepared from 10:1
dilution of the 50 mM stock with HEPES buffer.
Reaction
Stock Solution

Reaction
Concentration
1x

1

2

3

66

66

92.6

Batch 3 SrtApneu
(150 µM)

50 or 10 µM

33

33

6.7

NO2-alkyne
(50 or 10 mM)

500 µM

0.5

-

1*

H2O2 (2.0 mM)

15 um

-

-

0.75

HEPES Buffer (1x)
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6. Appendix I: NMR Spectra of Synthesized Compounds

(S)-5-(2-((((9H-fluoren-9-yl)methoxy)
carbonyl)amino)propanamido)-4 oxopentanoic acid

H
N

FmocHN
O

O
OH
O

Crude product (residual solvent contamination)
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tert-butyl (S)-4-((tert-butoxycarbonyl)amino)-3oxopentanoate

OtBu

BocHN
O

O
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tert-butyl 2-(((Trifluoromethyl)sulfonyl)oxy)acetate

O
TfO

OtBu

Crude product
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tert-butyl (R)-2-(((Trifluoromethyl)sulfonyl)oxy)propanoate

O
TfO

OtBu

Crude product
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(S)-5-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-oxohexanoic acid

O
FmocHN

OH
O

Contains solvent and residual starting material

109

